CDK4/6抑制剂在晚期乳腺癌内分泌治疗的临床研究进展  

Progress in clinical research of CDK4/6 inhibitors in endocrine therapy of advanced breast cancer

作　　者：饶彬[1] 吴耀忠[1] RAO Bin;WU Yaozhong(Department of Breast Surgery,Wuzhou Red Cross Hospital in Guangxi Zhuang Autonomous Region,Wuzhou543002,China)

机构地区：[1]广西壮族自治区梧州市红十字会医院乳腺外科,广西梧州543002

出　　处：《中国现代医生》2021年第26期188-192,共5页China Modern Doctor

摘　　要：乳腺癌位居我国女性恶性肿瘤的首位,内分泌治疗可给激素受体阳性/人表皮生长因子受体2阴性乳腺癌患者带来较好预后,但由于耐药出现,患者治疗获益下降。随着CDK4/6抑制剂的研发及临床研究的深入探索,晚期激素受体阳性乳腺癌的治疗效果得到提高,从而使晚期激素受体阳性乳腺癌的治疗模式发生改变。本文对CDK4/6抑制剂的机制及在晚期乳腺癌内分泌治疗中的临床研究进展进行综述。Breast cancer ranks first among female malignant tumors in our country.Endocrine therapy has better prognosis in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.However,due to the emergence of drug resistance,the treatment benefits decline.With the development of CDK4/6 inhibitors and in-depth exploration of clinical research,the therapeutic effect of advanced hormone receptor-positive breast cancer has been improved,which has changed the treatment model of advanced hormone receptor-positive breast cancer.This article reviewed the mechanism of CDK4/6 inhibitors and clinical research progress in endocrine therapy of advanced breast cancer.

关 键 词：乳腺癌 细胞周期 CDK4/6抑制剂 激素受体阳性 

分 类 号：R737.9[医药卫生—肿瘤]